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Abstract 
Previous studies have demonstrated that acute s t ress  or ovine corticotropin-releasing hormone (oCRH) in vivo, or oCRH in vitro, 
stimulates release of 8-endorphin over 8-lipotropin from anterior pituitary corticotropes. This occurs despite the predominance of 
j-Iipotropin in corticotrope peptide stores. In vitro studies with primary anterior pituitary cultures suggested that chronic exposure 
to oCRH results in a shift towards more P-lipotropin secretion into the media than with short-term exposure. The current studies 
explored whether increased secretory drive in vivo results in a similar shift towards more 8-lipotropin. We used removal of 
glucocorticoids by adrenalectomy or metyrapone blockade of corticosterone synthesis, to stimulate endogenous secretion of CRH 
and vasopressin. Both treatments resulted in shifts of the ratio of 8-endorphin : P-lipotropin in plasma of experimental animals in 
comparison to the sham-treated control rats. In vitro testing with oCRH of anterior lobe cultures from adrenalectomized or 
metyrapone-treated rats demonstrated similar effects of these treatments on the ratio of P-endorphin : 8-lipotropin. These changes 
occurred despite similar ratios of 8-endorphin : 8-lipotropin in anterior pituitary peptide stores. 
Adrenocorticotropin (ACTH) and P-endorphin are synthesized 
as part of a larger precursor molecule known as proopionielano- 
cortin (POMC). The anterior pituitary corticotrope processes the 
C-terminal region of POMC to ACTH and either 8- 
lipotropin (P-LPH) or 8-endorphin, with P-LPH predominating 
over 8-endorphin as the end product of processing by 2- to 
3-fold ( I .  2). Despite the predominance of 8-LPH over 8- 
endorphin in the total stores of anterior pituitary corticotropes, 
we have demonstrated that acute stress or  ovine corticotropin- 
releasing hormone (oCRH) in vitro leads to the preferential 
release of 8-endorphin over P-LPH from anterior lobe cortico- 
trope in rats (3). A similar preferential release of 8-endorphin 
over 1-LPH was demonstrated in man following oCRH infusion 
or electrically-induced seizures, suggesting that P-endorphin 
predominates over 8-LPH in the releasable pools of corticotropes 
(4, 5). However, the effects of chronic exposure to C R H  on the 
ratio of 8-endorphin to  8-LPH in the corticotrope’s releasable 
pools is less clear. Chronic C R H  exposure of anterior pituitary 
primary cell cultures has been shown to have a number of 
biosynthetic effects which could impact upon releasable pools in 
the corticotrope. For  example, continuous C R H  exposure in 
vitro leads to an increase in ACTH and P-endorphin/B-LPH 
released into the media over time as well as an increase in 
biosynthesis (6-8). The study of Wand et al. (8) using primary 
anterior pituitary cultures suggested that chronic CRH adminis- 
tration to these cultures leads to a proportionately greater release 
of P-LPH over P-endorphin in the media. Likewise, studies by 
Ham and Smyth (9, 10) also demonstrated changes in anterior 
corticotrope processing and secretion following in vitro exposure 
to oCRH. In vivo, the effects of chronic CRH administration on 
processing and forms secreted have not been explored. Since the 
stimulatory effects of CRH are balanced by the inhibitory effects 
of glucocorticoids on both corticotrope secretion and POMC 
biosynthesis in vivo, removal of the inhibitory effects of glucocort- 
icoids by adrenalectomy (ADX) can serve as a means of 
increasing endogenous C R H  release and consequently driving 
corticotrope secretion (6, 1 1-13). 
Following ADX there is a rapid increase in plasma ACTH 
and 8-endorphin immunoreactivity (TR). This leads to a depletion 
of anterior lobe ACTH content by 1 day ( 1  3). This depletion is 
accompanied by an increase in mRNA for POMC leading to an 
increase in POMC biosynthesis. After several days the cortico- 
trope ACTH content returns to normal, despite continued 
increased secretion of ACTH and 8-endorphin into plasma. In 
view of the absence of negative feedback of glucocorticoids on 
release, this increased activation continues to drive transcription 
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of POMC mRNA and POMC biosynthesis leading to an 
increased content and increased levels of POMC mRNA, similar 
to the situation with chronic CRH administration in vitro. This 
greatly increased secretory drive could impact upon the processing 
of P-LPH to 8-endorphin. 
In vivo more than one secretagog elicits corticotrope secretion. 
The removal of glucocorticoid negative feedback affects both 
C R H  and arginine vasopressin (AVP) secretion and results in 
expression of AVP in C R H  neurons and release of AVP into the 
hypophyseal portal blood (14). This induction of AVP can be 
seen following both ADX and treatment with metyrapone, an 
1 18-hydroxylase inhibitor of corticosterone synthesis ( 1  5). Thus, 
following glucocorticoid removal the anterior pituitary is exposed 
to both increased C R H  and AVP in a continuous rather than 
the usual pulsatile, circadian fashion. This sustained exposure to 
C R H  and AVP may have different consequences than CRH in 
vitvo. To evaluate the effects of increased secretory drive on the 
secretion of 8-endorphin and 8-LPH in vivo we utilized the 
removal of glucocorticoid negative feedback by either ADX or 
treatment with metyrapone as a stimulus to corticotrope secretion 
and biosynthesis. 
R esu I ts 
Plasma data 
ADX is followed by release of 8-endorphin-IR into plasma. A 
time course of plasma values is shown in Fig. 1. Each time point 
represents a mean of 3 sham and 5 to 6 ADX animals. As can 
be seen there is n o  difference between sham ADX and ADX 
animals a t  the 12 h time point. The low concentrations of 0- 
endorphin-IR in plasma of these 12 h ADX may be secondary 
to the tremendous decrease in anterior pituitary 8-endorphin-IR 
content (14% of sham ADX; Fig. I B ) .  By 3 days, there is an 
increase in plasma concentrations which persists to the final time 




To determine the ratio of 8-LPH t o  8-endorphin present in 
plasma, the plasma from 5 to  6 ADX animals for each ADX 
time point was pooled and applied to  a G-50 molecular sieving 
column. The plasma from two groups of shams (6 animals) was 
pooled to generate sham profiles. The sieving profiles from each 
pool of sham were similar, showing a very small amount of 8- 
LPH size and a large peak of fl-endorphin size material (ratio 
of 8-endorphin : 8-LPH = 27 6 : 1). These data are in agreement 
with all of our previous data on normal rats demonstrating a 
large amount of a-endorphin size material in plasma, a substantial 
portion of which is derived from intermediate lobe melanotropes. 
Despite similar plasma concentrations of 8-endorphin-IR between 
12 h sham ADX and 12 h ADX rats, there are already changes 
in the ratio of /J-LPH to 8-endorphin present in plasma (Fig. Ic) .  
At 12 h, the shams demonstrate a ratio of P-endorphin:P-LPH 
of 14: 1, while the ADX animals demonstrate a ratio of 0- 
endorphin to P-LPH of 3 :  1. At 24 h, there is a still greater 
increase in fl-LPH in the ADX rats so the ratio of a-endorphin : 8- 
LPH is now 1 .I : 1 .  By 3 days the ratio of b-endorphin : 8-LPH 
drops to 0.7: 1, indicating a predominance of P-LPH over b- 
endorphin at  this time point. At this same time point, the 
pituitary content o f  8-endorphin has returned to normal (Fig. 1B). 
At day 5, the ratio of 8-endorphin : p-LPH has returned to I : I .  
At day 10 the anterior pituitary content is now 3-fold higher 
than sham ADX and the ratio of P-endorphin : P-LPH in plasma 
is 1.5 : 1. At all these time points, sham ADX show a mean ratio 
of 8-endorphin : P-LPH of 27 6 : 1. 
ADX is accompanied by a substantial degree of surgical stress 
as well as removal of glucocorticoid negative feedback. In an 
attempt to reduce the stress and focus on removal of negative 
feedback, studies with metyrapone were undertaken. Metyrapone 
acts to block the last step in corticosterone synthesis and results 
in the secretion of 1 I-deoxycorticosterone rather than corticos- 
terone itself. A pilot study with metyrapone indicated no change 
in P-endorphin-IR concentrations at  24 h but increased plasma 
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FIG. 1. Time course experiment of plasma and pituitary response to ADX. The 8-endorphin release into plasma is shown in (A) (3,  sham; W ,  ADX). 
At 12 and 24 h, plasma 8-endorphin-IR concentrations are indistinguishable from shams. By day 3, there is increased secretion that persists through 
day 10. (B) The pituitary content demonstrates depletion of 8-endorphin stores at 12 and 24 h, with a return to normal by day 3. At day 10, the total 
peptide stores are elevated 3-fold over shams (0, sham; ., ADX). (c) The ratio of P-endorphin : 8-LPH in plasma following ADX as determined by 
molecular sieving. Although initial release at 12 h demonstrates more 8-endorphin than b-LPH, on days 1, 3 and 5 ,  the proportions of 8-endorphin 
and 8-LPH are approximately equal. By day 10, ,&endorphin begins to predominate again. 
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concentrations at 72 h (Fig. 2). A repeat experiment examined 
the effect of metyrapone on the ratio of P-endorphin : 8-LPH. 
The number of rats per group varied from 1 1  to 15, and is 
indicated in parenthesis in Table 1. In neither of the studies 
examining 24 h metyrapone treatment is the plasma level of P- 
endorphin-IR increased in comparison to DMSO-treated animals. 
In both studies the P-endorphin-IR was significantly increased 
at 72 h in comparison to DMSO-injected control (two-way 
ANOVA: experiment 1, metyrapone x day interaction, F= 6.3, 
df = 1, P = 0.01 8; experiment 2, metyrapone x day interaction, 
F=25.97, df= 1, P=O.OOOl). In neither of these studies is there 
a significant effect of metyrapone on P-LPH/P-endorphin anterior 
pituitary content at 24 or 72 h (Table 1) .  Studies currently in 
progress suggest there is an early rise in plasma P-endorphin-IR 
observable at 4 h but by 24 h plasma concentrations are back to 
normal. 
The plasma sieving data from metyrapone-treated animals are 
similar to the ADX group. The ratio of 8-endorphin : P-LPH in 
plasma of 24 h DMSO-treated animals is 12.1, while the mean 
ratio of /3-endorphin : P-LPH in plasma from 24 h metyrapone- 
treated animals is 1.5 : 1, an 8-fold difference in the ratio. Again, 
similar to the 12 h ADX data, this shift occurs despite the same 
plasma concentrations of total P-endorphin-IR. There is also 
little difference in the ratio of /3-endorphin : /3-LPH between the 
150r 
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FIG. 2. Plasma 8-endorphin-IR response to metyrapone (MET) treatment 
for 24 and 72 h. No change in plasma P-endorphin-IR was seen at 24 h, 
but there was a significant increase in plasma 0-endorphin-IR at 72 h. 
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24 and 72 h metyrapone-treated rats, despite elevated plasma 
concentrations of P-endorphin-IR at 72 h. In both the 24 and 
72 h metyrapone-treated groups, 8-endorphin size material is the 
predominant form in plasma. A repeat study examined the 24 h 
time point, and anterior pituitaries were tested for their in vitro 
response to CRH. In this study, plasma P-LPHIP-endorphin 
concentrations were again similar between groups. (DMSO = 
72 f 9, metyrapone = 58 f 9; n = 6, 7 per group). Plasma sieving 
demonstrated a 9-fold shift in the ratio of 8-endorphin : 8-LPH 
to favor more P-LPH as seen in the previous studies. 
Response of anterior pituitary in vitro 
To confirm that changes in plasma ratios of 1-endorphin : P- 
LPH were due to shifts in anterior lobe corticotrope release, 
anterior pituitary cell suspensions from control and treated rats 
were tested in vitro with oCRH. Both unhandled control rats 
and DMSO-treated rats were included as control groups. The 
pituitaries from 6 rats per group were pooled. Following 
dispersion of anterior pituitary cells into single cell preparations, 
aliquots of cells were stimulated for 1 h with oCRH. The media 
from the dispersed anterior pituitary cells stimulated with oCRH 
were assayed for total 8-endorphin-IR then applied to a (3-50 
sieving column. All pituitary cell preparations demonstrated an 
increased release of P-endorphin-IR with CRH stimulation 
(Fig. 3a). The sieving data are shown in (Fig. 3B). The baselinc 
(unstimulated secretion) from unhandled control pituitary cells 
show 1.5-fold more 8-LPH than 8-endorphin; the pituitary cells 
from DMSO-treated rats demonstrate equal parts of P-LPH and 
P-endorphin secreted into the media. These are in agreement 
with our pilot as well as previous studies (2) demonstrating 
approximately equal parts of P-LPH and a-endorphin or a 
predominance of P-LPH in unstimulated release from anterior 
pituitaries from normal rats. In contrast, the pituitaries from 
metyrapone-treated rats show 2-fold more P-endorphin than P- 
LPH secretion at baseline (unstimulated secretion). Following 
stimulation with oCRH, the ratio of P-endorphin to 8-LPH 
released (total minus unstimulated) changes for the various 
groups (Fig. 3). The unhandled control and DMSO-treated 
groups demonstrate a mean ratio of /I-endorphin : /3-LPH of 
2.0 f 0.1 : 1 .  The pituitaries from metyrapone-treated animals 
demonstrate a ratio of 1.1 : 1. These data are consistent with in 
vivo plasma data suggesting that chronic drive leads to proportion- 
ately more P-LPH in the releasable pool. The differences in 
forms released in these short-term suspensions are not due to 
differences in the ratio of /3-LPH and p-endorphin in the total 
stores (Table 2). Both DMSO-treated and metyrapone-treated 
TABLE 1. Effect of Metyrapone Treatment on Plasma P-Endorphin, Ratio of P- 
Endorphin to P-LPH in Plasma and Anterior Pituitary 8-Endorphinlb-LPH Content. 
Plasma 8-endorphin-IR Plasma ratio Anterior pituitary 
(xkSEM) 0-endorphin : 8-LPH 8-endorphin-IR 
content (pmoles/pit) 
(x SEM) 
24 h DMSO (11) 85k9  12: 1 98 k 26 
24 h Metyrapone (12) 68+20 1.5: 1 92 k 34 
72 h DMSO (15) 73k  14 6 :  1 139k26 
72 h Metyrapone (1 5 )  247 3 1 1.2: 1 130k26 
The number of rats per group is indicated in parenthesis. 
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FIG. 3. Pituitary 8-endorphin response to oCRH in metyrapone (MET)-treated rats tested in vitro. The response to oCRH is small in pituitaries from 
rats given metyrapone for 24 h (A). Likewise, the stores of b-endorphin may be depleted (c). The proportion of 8-endorphin to 8-LPH secreted into 
media at baseline and in response to oCRH stimulation, as determined by molecular sieving, is shown in (B). Both unhandled control (CONT) and 
vehicle-treated control (DMSO) demonstrate predominantly b-LPH at baseline. and 2-fold more 8-endorphin than 8-LPH following stimulation. In 
contrast, metyrapone-treated rats demonstrate more 8-endorphin at baseline, with a shift towards more 8-LPH following oCRH stimulation. (A and 
B): 0, unstimulated: a. +oCRH (1 nM). 
 TABLE^. Effect of Metyrapone Treatment on Ratio P- equal proportions of B-LPH and /3-endorphin released into the 
Endorphin : 8-LPH Released by oCRH and Ratio b- media. Both oCRH and AVP stimulated 2-fold more /%endorphin 
Endorphin : P-LPH in Anterior Pituitary Stores. than P-LPH. 
8-LPH 8-Endorphin Ratio b-endorphin : 8-LPH 
A. Anterior lobe suspensions media = /?-endorphin-IR released 
Control 177 367 2.1 : 1 
DMSO 311 593 1.9: I 
Metyrapone 118 136 1 . 1 :  1 
B. Anterior lobe cells 
Control 538 42 1 0.8: 1 
DMSO 389 207 0.5: 1 
Metyrapone 298 156 0.5: I 
rats demonstrate similar ratios of P-endorphin : P-LPH in the 
anterior pituitaries (0.5 : 1) but release different proportions of 
P-endorphin : a-LPH in response to oCRH in vitro. A similar in 
vitro study was conducted with anterior pituitary cell suspensions 
from sham and 24 h ADX rats. The ADX rats demonstrate a 
greater ratio of P-endorphin : P-LPH in anterior pituitary cells 
than the sham ADX rats (0.5: 1 in sham; 0.8: 1 in ADX), but 
sham rats release proportionately more P-endorphin in response 
to oCRH in vitro (ratio of 8-endorphin: P-LPH 1.9: 1 in sham 
and I .2 : 1 in ADX). 
Since both ADX and metyrapone treatments are accompanied 
by increases in both C R H  and AVP secretion in vivo, the final 
experiment examined whether CRH and AVP may recruit 
different corticotrope populations that secrete different propor- 
tions of P-endorphin : 8-LPH. Anterior pituitaries from normal 
rats were prepared into single cell preparations, then challenged 
with oCRH or AVP. Following 1 h of challenge, the media were 
collected and sieved. The basal unstimulated release demonstrated 
Discussion 
These data support in vitro data suggesting that increased 
secretory drive results in a shift in the ratio of b-endorphin : P- 
LPH released from the anterior pituitary. The ADX data provide 
the strongest in vivo support for this hypothesis. At 12 h following 
ADX, there is 3-fold more P-endorphin than /I-LPH in plasma. 
By 24 h following ADX, the ratio of P-endorphin:P-LPH in 
plasma has dropped to 1. I : I ,  although the plasma concentrations 
of P-endorphin-IR are not elevated at this time. Since the 
conditions of the P-endorphin RIA strongly prefer carboxytermi- 
nal intact B-endorphin over the carboxyterminal shortened forms 
released from intermediate lobe, these data suggest that the 
anterior lobe contributes to  the P-endorphin pool in control rats, 
and that the changes seen in the ratios of P-endorphin : P-LPH 
following ADX represent changes in anterior lobe secretion. The 
ADX data are further supported by the 24 h metyrapone 
treatment data, where plasma concentrations of P-endorphin-IR 
are unchanged by metyrapone treatment but there is an 8- to 
9-fold shift in the ratio of P-endorphin : P-LPH to favor 8-LPH 
secretion. In the ADX time course experiment, approximately 
equal parts of P-LPH and P-endorphin are present in plasma 
until the 10 day point when P-endorphin again predominates. 
The increased proportion of 8-LPH in plasma a t  early time 
points could be secondary to  the longer half-life of /I-LPH in 
comparison to P-endorphin. However, a longer half-life of b- 
LPH is not the sole reason for these changes in ratio of 8- 
endorphin : 8-LPH since there appears to be an increasc in this 
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ratio a t  later time points in the ADX rats, when plasma secretion 
and concentration of P-endorphin-IR are greatly elevated in 
ADX rats. Particularly a t  10 days, the time point when plasma 
/I-endorphin-IR concentrations are the highest following ADX, 
the ratio of 8-endorphin: 8-LPH has returned to  1.7: 1. A 
previous study also demonstrated a shift in the ratio of 8-LPH 
to P-endorphin secreted into plasma to  favor more 8-endorphin 
in 14 day ADX as compared to 7 day ADX rats (16). 
While both metyrapone and  ADX result i n  removal of 
glucocorticoid negative feedback, metyrapone treatment results 
in only a partial blockade of  glucocorticoids, with approximately 
40% to 50% block in authentic corticosterone production (17). 
Consequently, ADX versus metyrapone-treated groups differ in 
concentrations of circulating glucocorticoids. However, both 
treatments d o  result in increased secretion, and  both treatments 
result in a shift in the ratio of 8-endorphin:P-LPH in plasma, 
even a t  the 24 h time point when there is no change in  circulating 
plasma concentrations between the treated groups and  their 
respective controls. In  part, this may  result from significant early 
release in both A D X  and  metyrapone-treated rats, which resulted 
in a relative depletion of  8-endorphin in the releasable pool. The  
in vitro data further demonstrate that  anterior pituitaries f rom 
control or DMSO-treated rats release approximately 2-fold more 
&endorphin than 8-LPH with oCRH challenge, while anterior 
pituitaries from metyrapone-treated rats demonstrate a 1 : 1 ratio 
of P-endorphin : P-LPH following oCRH challenge. This differ- 
ence in release is not  accounted for by changes in the ratio of 8- 
endorphin : P-LPH present in the anterior pituitaries; both 
DMSO- and metyrapone-treated rat pituitaries demonstrate 
ratios of P-endorphin : P-LPH of 0.5 : 1, but release different 
proportions of 8-endorphin : 8-LPH following oCRH challenge. 
These in vitro da ta  are in agreement with in vitro da ta  of H a m  
and Smyth (9, 10) suggesting that brief exposure of  anterior 
pituitary primary cell cultures to  oCRH resulted in primarily 8- 
endorphin release, but chronic exposure to oCRH shifted the 
release to predominantly P-LPH. 
In conclusion, these data provide strong support  for the 
hypothesis that  chronic CRH drive leads to  changes that  alter 
the mixture of products in secretory granules of anterior lobe 
corticotropes. These changes are difficult t o  predict based upon 
molar ratio of precursor and products present in the corticotrope 
cells. In part, this may result f rom the inclusion of  a number of  
immature and newly synthesized granules not present in the 
readily releasable pool in quantitation of  P-LPH and P-endorphin 
stores. This suggests that the initial processing step yielding 8- 
LPH and the 22K ACTH intermediate is quite rapid, while the 
processing o f  8-LPH to /?-endorphin is rate limiting in times o f  
chronic drive. This processing enzyme may be inducible at later 
time points as suggested by 10 day ADX data.  These changes in 
the mixture of secretory products i n  the releasable pool can lead 
to changes in the messages delivered to target organs in situations 
of chronic demand. 
Materials and Methods 
Treatments 
Male Sprague-Dawley rats (175 to 250 g) obtained from Charles River 
(Portage, MI, USA) were maintained in a controlled environment on a 
12 h light/dark schedule. Animals were given 5 to 7 days to adapt to the 
new environment before the initiation of treatments. ADX were done 
with a dorsal surgical approach under chloral hydrate anesthesia. ADX 
animals were given 0.9% NaCl in their drinking water following the 
surgery. The completeness of ADX was verified by measurement of 
plasma corticosterone in blood obtained at the time of sacrifice. 
Metyrapone was obtained from Sigma (St. Louis, MO, USA). It was 
dissolved in DMSO and administered 200 mg/kg subcutaneously every 
8 h. A final injection was given 30 to 60 min before sacrifice. Control 
animals received DMSO injections at the same time points. In some cases 
an unhandled control group is included as a further control for thc stress 
of injection. Animals were sacrificed by decapitation and trunk blood 
was collected in K +  EDTA tubes for hormonal measurements. Metyrap- 
one- and DMSO-treated rats were sacrificed at 1700 h, at the peak of 
circadian drive, except in the final experiment involving in vitro testing 
of anterior pituitaries. In all studies, pituitaries were dissected into anterior 
and neurointermediate lobes and the portion of the anterior lobe under- 
lying the neurointermediate lobe was discarded. This prevents contamina- 
tion of the anterior pituitary fragments with intermediate lobe 
melanotropes. At the time of sacrifice, anterior pituitary fragments were 
frozen on dry ice for measurement of content or placed in Krebs-Ringer 
bicarbonate buffer until further processing for short-term anterior lobe 
suspensions. 
Tissue processing 
Plasma was extracted with Sep-Pak C,, cartridges for /?-endorphin-IR 
measurements as previously described (17). An aliquot of this eluate was 
used for corticosterone measurement. Anterior pituitaries were extracted 
with LET (lithium, EDTA, tris) extraction medium to permit quantitation 
of mRNA and RIA on the same sample. An aliquot equal to 1/30 of the 
anterior pituitary was taken for peptide measurement before the addition 
of proteinase K. This peptide aliquot was diluted in an acid: acetone 
extraction medium (3 : 1 mixture acetone: 0.2 N HCI) and centrifuged. 
The supernatant was saved then lyophilized prior to RIA. Studies in our 
laboratory have validated similar recovery of /?-endorphin-IR with LET 
extraction and the acid: acetone extraction method that we have used 
previously. 
Anterior lobes used for in vitro response to oCRH and AVP were 
processed as previously described (18). Briefly, the anterior pituitaries 
were treated with collagenase for 60 min (3 mg/ml; Sigma) to obtain a 
single cell preparation, filtered through 50 pm nylon mesh to remove 
fibrin and clumps, then washed in Krebs to remove collagenase. The cells 
were preincubated for 90 min in Krebs under 95% 0 2 / 5 %  CO, to stabilize 
the suspensions. After preincubation, the cells were centrifuged (100 x g) 
and fresh medium containing desired secretagogs was added to aliquots 
of the cell suspension. All concentrations of secretagogs were run in 
triplicate, and the medium from the triplicates pooled for extraction and 
hormonal measurement. Baseline secretion was assessed in two separate 
aliquots of the cell suspensions. Secretagogs oCRH and AVP were added 
in 1 nM and 10 nM concentrations, respectively. The incubations were 
conducted at 37°C in a water bath under 95% 0,/5% CO,. Following 
60 min, these cells were centrifuged and the media saved for extraction 
with Sep-Pak Cls cartridges using the same extraction as plasma. The 
cells were lysed by freezing and thawing in 5 N acetic acid with 0.5% 
bovine serum albumin (Sigma). Following centrifugation, the supernatant 
was removed and lyophilized for future RIA. 
Hormonal assays 
The P-endorphin assay utilized an antibody raised against /?-endor- 
phin,-,, human sequence [P-endorphin,-,,,,J used at a final dilution of 
1/40,000. This is primarily a midportion antibody that shows 100% cross- 
reactivity with P-LPH and POMC under the condition of this assay. 
['251]~-endorphinl-,l(hl was used as the standard. The samples and 
standards were dissolved in 0.1 YO human serum albumin (Fraction V; 
Sigma) which was acidified to pH 3.0 with 1 N HCI. Samples from each 
rat were assayed prior to pooling for molecular sieving of /?-endorphin- 
IR. Under the conditions of the assay, this antibody showed 50% to 
85% cross-reactivity with various N-terminal acetylated forms of P- 
endorphin-IR. 
Aliquots of Sep-Pak extracted plasma were taken for corticosterone 
assay and were lyophilized, then extracted in ethanol saline and assayed 
using a competitive protein binding assay as previously described (18). 
[3H]Corticosterone was used as the label and unlabelled corticosterone 
as the standard. This assay measures all steroids and is not useful for 
studies with metyrapone-treated animals since 1 1-deoxycorticosterone is 
120 b-Endorphin/b-lipotropin release with diminished glucocorticoid secretion 
fully capable of displacing corticosterone in the competitive protein 
binding assay. 
Gel filtration 
To determine the molecular forms of a-endorphin-IR present in plasma, 
media and cell extracts, samples from rats from the same treatment 
groups were pooled and applied to a 90 x 1.5 cm G-50 molecular sieving 
column. The column was developed in I %  formic acid. Fractions of 
2.2 ml sizc were collected. The fractions were lyophilized, then resuspended 
in 0.1% HSA as previously described for RIA. 
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